214 related articles for article (PubMed ID: 36497434)
1. ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors.
Yi Q; Pu Y; Chao F; Bian P; Lv L
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497434
[TBL] [Abstract][Full Text] [Related]
2. Integrated analysis and validation reveal ACAP1 as a novel prognostic biomarker associated with tumor immunity in lung adenocarcinoma.
Wang N; Zhu L; Xu X; Yu C; Huang X
Comput Struct Biotechnol J; 2022; 20():4390-4401. PubMed ID: 36051873
[TBL] [Abstract][Full Text] [Related]
3. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
[TBL] [Abstract][Full Text] [Related]
4. Expression of ACAP1 Is Associated with Tumor Immune Infiltration and Clinical Outcome of Ovarian Cancer.
Zhang J; Zhang Q; Zhang J; Wang Q
DNA Cell Biol; 2020 Sep; 39(9):1545-1557. PubMed ID: 32456571
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer.
Zou Q; Wang X; Ren D; Hu B; Tang G; Zhang Y; Huang M; Pai RK; Buchanan DD; Win AK; Newcomb PA; Grady WM; Yu H; Luo Y
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34548385
[TBL] [Abstract][Full Text] [Related]
6. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
7. Immunological Value of Prognostic Signature Based on Cancer Stem Cell Characteristics in Hepatocellular Carcinoma.
Xu Q; Xu H; Chen S; Huang W
Front Cell Dev Biol; 2021; 9():710207. PubMed ID: 34409040
[No Abstract] [Full Text] [Related]
8. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
9. PTPRO-related CD8
Dong H; Xie C; Yao Z; Zhao R; Lin Y; Luo Y; Chen S; Qin Y; Chen Y; Zhang H
Front Immunol; 2022; 13():947841. PubMed ID: 36003382
[TBL] [Abstract][Full Text] [Related]
10. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
11. CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma.
Hu ZW; Sun W; Wen YH; Ma RQ; Chen L; Chen WQ; Lei WB; Wen WP
Front Immunol; 2022; 13():952059. PubMed ID: 36045683
[TBL] [Abstract][Full Text] [Related]
12. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
13. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
14. Deletion of Cbl-b inhibits CD8
Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
[TBL] [Abstract][Full Text] [Related]
15. MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients.
Wang G; Miao C; Mo L; Kahlert UD; Wu J; Ou M; Huang R; Feng R; Pang W; Shi W
Front Immunol; 2022; 13():1048503. PubMed ID: 36582246
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Analysis of Immune Implications and Prognostic Value of SPI1 in Gastric Cancer.
Huang J; Chen W; Jie Z; Jiang M
Front Oncol; 2022; 12():820568. PubMed ID: 35237521
[TBL] [Abstract][Full Text] [Related]
17. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
18. Pan-Cancer Molecular Characterization of m
Zhu J; Xiao J; Wang M; Hu D
Front Oncol; 2020; 10():618374. PubMed ID: 33585244
[TBL] [Abstract][Full Text] [Related]
19. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of LECT2 and relevance to immune infiltration in hepatocellular carcinoma.
Qin J; Sun W; Zhang H; Wu Z; Shen J; Wang W; Wei Y; Liu Y; Gao Y; Xu H
Front Genet; 2022; 13():951077. PubMed ID: 36160006
[No Abstract] [Full Text] [Related]
[Next] [New Search]
